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Abstract
Background: The distribution and the potential gene-gene and gene-environment interaction of
selected metabolic genetic polymorphisms was investigated in relation to gastric cancer risk in an
Italian population.
Methods: One hundred and seven cases and 254 hospital controls, matched by age and gender,
were genotyped for CYP1A1, CYP2E1, mEH, GSTM1, GSTT1, NAT2 and SULT1A1 polymorphisms.
Haplotype analysis was performed for EPHX1 exons 3 and 4, as well as CYP2E1 RsaI (*5 alleles) and
CYP2E1 DraI (*5A or *6 alleles). The effect modification by alcohol and cigarette smoking was tested
with the heterogeneity test, while the attributable proportion (AP) was used to measure the
biological interaction from the gene-gene interaction analysis.
Results: Gastric cancer risk was found to be associated with the inheritance of GSTT1 null
genotype (OR = 2.10, 95%CI: 1.27–3.44) and the SULT1A1 His/His genotype (OR = 2.46, 95%CI:
1.03–5.90). No differences were observed for the haplotype distributions among cases and
controls. For the first time an increased risk was detected among individuals carrying the *6 variant
allele of CYP2E1 if ever-drinkers (OR = 3.70; 95%CI: 1.45–9.37) with respect to never-drinkers (OR
= 0.18; 95% CI: 0.22–1.46) (p value of heterogeneity among the two estimates = 0.001). Similarly,
the effect of SULT1A1 variant genotype resulted restricted to ever-smokers, with an OR of 2.58
(95%CI: 1.27–5.25) for the carriers of His allele among smokers, and an OR of 0.86 (95%CI: 0.45–
1.64) among never-smokers (p value of heterogeneity among the two estimates = 0.03). The gene-
gene interaction analyses demonstrated that individuals with combined GSTT1 null and NAT2 slow
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acetylators had an additional increased risk of gastric cancer, with an OR of 3.00 (95%CI: 1.52–5.93)
and an AP of 52%.
Conclusion: GSTT1, SULT1A1 and NAT2 polymorphisms appear to modulate individual's
susceptibility to gastric cancer in this Italian population, particularly when more than one
unfavourable genotype is present, or when combined with cigarette smoke. The increased risk for
the carriers of CYP2E1*5A or *6 alleles among drinkers need to be confirmed by larger prospective
studies.
Background
Gastric cancer is the second most common cause of mor-
tality from cancer, with 647,000 deaths reported world-
wide in 2002 [1]. In many populations, particularly in
high-income countries, in the last decades its incidence
has gradually decreased, however it still represents the
fifth most common type of cancer in Europe and the
fourth internationally [1]. The development of gastric can-
cer appears to be the result of a complex interaction
between lifestyle and genetic factors. Among the lifestyle
and related risk factors, Helicobacter pylori infection,
tobacco smoking, a high intake of salt and lack of food
refrigeration all seem to play a major role [2]. Addition-
ally, gastric cancer shows a familial clustering [3]. With
regards to genetic factors, several Single Nucleotide Poly-
morphisms (SNPs) might potentially alter the individual
susceptibility to gastric cancer, among them genes coding
for metabolic enzymes [4].
A major part of carcinogenic substances require metabolic
activation by enzymes to be genotoxic, and inherited var-
iations in carcinogens metabolizing genes may alter
enzyme activity and subsequently carcinogens activation
or deactivation. Phase I enzymes, including Cytochrome
P450 (CYP) and microsomal Epoxide Hydrolase (mEH),
activate several compounds to form genotoxic elec-
trophilic intermediates. Activated metabolites are then, in
part, detoxified by phase II enzymes, such as glutathione
S-transferase (GST), N-acetyltransferase (NAT) and Sul-
fotransferase (SULT) [5]. We recently showed, for the first
time, that SULT1A1 Arg213His polymorphism might
affect the risk of gastric cancer [6], while contradictory
results concerning several SNPs in metabolic genes have
been reported [7-15].
Based on the knowledge that metabolic genes are pre-
sumed to modulate an individual's susceptibility to can-
cer by interacting with carcinogens, and since the
inheritance of several unfavourable genotypes is supposed
to additionally increase the risk of gastric cancer [8,9,11],
this hospital-based case-control study aims to investigate
the effect on gastric cancer of selected SNPs of CYP1A1,
CYP2E1, mEH, GSTM1, GSTT1, NAT2, SULT1A1, and their
differential effect according to tobacco smoking and alco-
hol habits. We also investigated to what extent the inher-
itance of more than one unfavourable genotype affects the
risk of gastric cancer.
Methods
Study population
The study subjects were selected according to a case-con-
trol study design as previously described [16]. Briefly,
cases were consecutive primary gastric adenocarcinoma
patients, with histological confirmation, who underwent
a curative gastrectomy in the "A. Gemelli" teaching hospi-
tal, located within the Università Cattolica del Sacro
Cuore in Rome. We defined gastric cancer cases as includ-
ing International Classification of Disease Ninth revision
codes 151.0–151.9. Controls were selected from cancer-
free patients, with a broad range of diagnoses including
around 15% of blood donors, admitted to the same hos-
pital during the identical time period and were frequency
matched to cases for age (± 5 years) and gender. All sub-
jects were Caucasians born in Italy. According to the Lau-
ren histotype classification [17], the majority (57.8%) of
the gastric cancer cases were intestinal. The tumours were
located in the antrum (39.3%), in the corpus (14.8%), in
the antrum/corpus (28.0%), in the cardia (10.3%),
stumps (5.6%) and in the fundum (2.0%). Based on the
cytological and architectural atypisms, as well as the histo-
pathological reports [18], patients' tumours were classi-
fied accordingly: 68.3% scarcely differentiated, 29.2%
moderately differentiated, 2.5% well-differentiated, while
53.8% were staged I–II and 46.2% staged III–IV. With a
response rate of 95% and 90% respectively for cases and
controls, 102 gastric cancer and 254 controls were
recruited.
A venous blood sample was drawn from each participant,
collected into an EDTA-coated tubes from which DNA
was isolated from peripheral blood lymphocytes. The
study was approved by the local review board and written
informed consent was obtained from each subject. The
procedures followed were in accordance with the Helsinki
Declaration.
Data collection
Cases and controls were interviewed by trained medical
doctors using a standard questionnaire to elicit informa-
tion on demographic variables, tobacco smoking (includ-
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ing cigarette, cigar and pipe) and drinking history, dietary
habits and family history of cancer. Questions pertaining
to lifestyle focused on the time period ending one year
prior to diagnosis. Smoking status was categorized as
never and ever-smokers (including both current and
former smokers) and alcohol consumption as drinkers/
non-drinkers (the latter including individuals whose alco-
hol intake less than 7 g/day). Fruit and vegetables intake
was classified as high if the participant consumed at least
two portions of fruit and two portions of vegetables per
day. Meals salt addition was referred to the use of adding
salt to the entrées during the main meals. Family history
(including non-melanoma skin cancer) of cancer referred
to parents, siblings and offspring. Data concerning previ-
ous Helicobacter pylori infection was not available for
either cases or controls. The response rate for completing
the interview was 99.1% for cases (106/107) and 99.6%
(253/254) for controls, with the exception of data relating
to a family history of cancer [unknown in 7.4% (8/107)
of cases and 3.5% (9/254) of controls].
Genotyping
GSTM1 and GSTT1 null alleles were identified using a
multiplex-Polymerase Chain Reaction (PCR)-based
method as described by Arand et al. [19]. The polymor-
phic site at nucleotide 638 in exon 7 (Arg213His) of the
SULT1A1 gene was genotyped by PCR-Restriction Frag-
ment Length Polymorphisms (RFLP) analysis as described
by Coughtrie et al. [20]. Identification of the mEH exon 3
(Tyr113His) and exon 4 (His139Arg) polymorphisms was
performed using a RFLP-based method [21]. CYP1A1 3'-
flanking region MspI polymorphism (CYP1A1*2A allele),
CYP2E1 RsaI polymorphism (CYP2E1*5 alleles) and
CYP2E1 DraI (*5A or *6 alleles) were also determined by
PCR-RFLP analyses (21). Three known slow acetylator
alleles, NAT2*5A, *6A and *7A were identified as previ-
ously described by Peluso et al [22]. Fast acetylator geno-
types are the homo-heterozyogous wild-type alleles
(*4A), slow acetylator genotypes are those with 2 slow
acetylator alleles [23]. Quality control for each genotyping
was performed in each experiment, and 10% of the total
samples were randomly selected and reanalyzed with
100% concordance. The analyst was blinded to the case or
control status of the samples.
Statistical analysis
The relationship between gastric cancer and putative risk
factors were measured using the adjusted odds ratios
(ORs) and their 95% CI derived from logistic regression
analysis using STATA software (version 8.2). We consid-
ered possible risk factors for gastric cancer as potential
confounders if the addition of that variable to the model
changed the OR by 10% or greater. Confounding checks
were performed in both of the univariate and final multi-
variate models. If a factor was identified as a confounder
of any estimated main effect, it was kept in all models.
Based on these criteria, we controlled for age, gender, alco-
hol consumption and family history of cancer, when
appropriate. In the multivariable model, we adjusted for
the continuous variables of age and alcohol (g/day).
The genotypes of GSTM1 and GSTT1 were dichotomized
according to the presence versus absence of the null allele,
and NAT2 was dichotomized according to the inferred
phenotype (slow versus fast). We analyzed exon 3 and
exon 4 mEH genotypes by "imputed phenotype" as sug-
gested from Smith and Harrison [24]. Lastly, we con-
ducted haplotype analysis for EPHX1 exons 3 and 4, as
well as CYP2E1*5 and *5A or *6 using Cocaphase soft-
ware. Hardy-Weinberg Equilibrium (HWE) was tested for
separately all of the case and control SNPs.
In order to assess if the effect of the studied polymor-
phisms is modified by tobacco smoking and alcohol con-
sumption, we performed a stratified logistic regression
analysis. An heterogeneity test was then used to test differ-
ences among the strata.
Biological interaction between two genes was estimated
using departure from additivity of effects as the criterion
of interaction, as suggested by Rothman [25]. To quantify
the amount of interaction, the attributable proportion
(AP) due to interaction was calculated as described by
Andersson et al [26]. The AP due to interaction is the pro-
portion of individuals among those exposed to the two
interacting factors that is attributable to the interaction
per se and it is equal to 0 in the absence of a biological
interaction [25]. Finally, in order to test for more than
multiplicative effect among two genes, the likelihood
ratio test was used, with the homozygous wild-type indi-
viduals for both genes as the reference group.
Results
General characteristics of the study population are pre-
sented in Table 1. Alcohol consumption and family his-
tory of cancer were associated with an increased risk of
gastric cancer, with ORs of 2.10 (95% CI: 1.22–3.60) and
an OR of 1.93 (95%CI: 1.14–3.26), respectively (Table 1).
The genotype frequencies of our control group were in
line with those for Caucasians and were in HWE both for
cases and controls (p > 0.05) [5,20]. As shown in Table 2,
we found a significant difference in the distribution of
GSTT1 null and SULT1A1 His/His genotype amongst
cases and controls: 37.1% versus 22.4% (OR = 2.10, 95%
CI: 1.27–3.44) and 10.3% versus 5.1% (OR = 2.46; 95%
CI: 1.03–5.90), respectively. An increased risk was also
detected for NAT2 slow acetylators (OR = 1.38, 95% CI:
0.88–2.19), however not statistically significant. Haplo-
type analyses indicated that there was no significant link-
age disequilibrium between EPHX1 exons 3 and 4, as well
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Table 1: Odds Ratios (95% CI) of gastric cancer according to the collected variables and their frequency distribution among 107 cases 
and 254 controls
Cases % (n) Controls % (n) OR (95% CI) †
Age (years ± SD) 66.4 ± 12.0 64.0 ± 12.8 -
Male gender 52.3 (56) 55.5 (141) -
Alcohol drinkers
Non-drinkers° 29.9 (32) 47.6 (121) 1*
Drinkers 70.1 (73) 52.4 (133) 2.10 (1.22–3.60)
Smoking status
Never 53.3 (57) 57.5 (146) 1*
Ever 46.7 (50) 42.5 (108) 1.10 (0.64–1.90)
Fruit and vegetables intake
High‡ 20.0 (21) 15.8 (40) 1*
Low 80.2 (85) 84.2 (213) 0.95 (0.50–1.90)
Grilled meatd 2 times/month 52.3 (56) 48.4 (123) 1*
> 2 times/month 47.7 (61) 51.6 (131) 0.99 (0.60–1.66)
Meals salt addition^
No 85.1 (91) 92.9 (235) 1*
Yes 14.9 (16) 7.1 (18) 1.70 (0.78–3.67)
Familiarity for cancer
No 61.6 (61) 78.4 (192) 1*
Yes 38.4 (38) 21.6 (53) 1.93 (1.14–3.26)
Familiarity for gastric cancer
No 88.0 (88) 94.4 (237) 1*
Yes 12.0 (12) 5.6 (14) 1.88 (0.80–4.44)
* Reference category; † OR adjusted for age, gender, alcohol consumption and familiarity for cancer; ‡ High fruit and vegetables consumption is 
defined as at least 2 portions of fruit and 2 portions of vegetables per day; ° Non-drinkers defined as an alcohol intake less than 7 g/day; ^ adding salt 
to the entrées during the main meals
Table 2: Odds Ratios (95% CI) of gastric cancer for SNPs in metabolic genes and their frequency distribution among 107 cases and 254 
controls
Cases % (n) Controls % (n) OR (95% CI) * †
GSTM1 null 56.2 (59) 52.7 (135) 1.13 (0.71–1.79)
GSTT1 null 37.1 (39) 22.4 (57) 2.10 (1.27–3.44)
CYP1A1*2A 20.5 (22) 22.0 (56) 0.88 (0.50–1.54)
CYP2E1*5 4.7 (5) 7.8 (20) 0.54 (0.20–1.50)
CYP2E1*5A or *6 14.5 (15) 10.6 (27) 1.33 (0.67–2.65)
NAT2 Slow ‡ 59.8 (64) 51.8 (131) 1. 38 (0.88–2.19)
SULT1A1 Arg/His 36.5 (39) 33.5 (85) 1.35 (0.82–2.21)
His/His 10.3 (11) 5.1 (13) 2.46 (1.03–5.90)
EPHX1 exon 3 Tyr/His 38.7 (41) 36.0 (90) 1.24 (0.76–2.04)
His/His 14.1 (15) 11.2 (28) 1.37 (0.67–2.80)
EPHX4 exon 4 His/Arg 30.5 (32) 37.4 (95) 0.77 (0.47–1.27)
Arg/Arg 5.7 (6) 2.4 (6) 2.28 (0.70–7.20)
Imputed mEH phenotypes ^ Rapid 15.8 (15) 23.7 (59) 0.60 (0.30–1.15)
Slow 25.3 (24) 21.2 (54) 1.00 (0.55–1.78)
Very slow 8.4 (8) 8.6 (21) 0.82 (0.33–2.00)
* OR adjusted for age and gender
† Reference groups are the homozygous wild genotypes for each gene
‡ Reference group is fast acetylators (homo-heterozygous for the wild-type allele)
^ Reference group is the normal imputed phenotype
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as CYP2E1*5 and *5A or *6, amongst the cases and the
controls. Furthermore, the frequency of the estimated
haplotypes was the same among the groups (data not
shown).
From the stratified analysis according to smoking status
(Table 3), the significant association for SULT1A1
observed in the overall analysis seems to be limited to ever
smokers, with a p value for heterogeneity among the two
strata of 0.03 (Table 3). On the other hand, the increased
risk for GSTT1 null individuals was significant regardless
of the smoking status (Table 3). As for the effect modifica-
tion by alcohol habits, drinking subjects carrying the var-
iant allele of CYP2E1 (*5A or *6 alleles) had an OR of
3.70 (95%CI: 1.45–9.37) of gastric cancer compared to
those drinking without the variant allele, with the result of
the heterogeneity test among the strata showing a signifi-
cant effect modification by alcohol (p value = 0.001, Table
3).
To reduce the chance of multiple testing, we limited the
gene-gene interaction analyses to the three SNPs that
exhibited the most prominent association with gastric
cancer. It was observed that in all of the combinations
individuals carrying two risk genotypes had an additional
risk compared to those with only one risk genotype, with
an AP greater than 0, however there was no evidence of
multiplicative interaction (p values > 0.05, Table 4). The
observed effect was particularly high amongst individuals
with both GSTT1 null and NAT2 slow (OR = 3.00, 95%
CI: 1.52–5.93; AP = 52%) (Table 4). Additionally, by strat-
ifying these data according to smoking status (data not
shown), ever-smoker individuals with combined GSTT1
null and NAT2 slow had an OR of 4.23 (95% CI: 1.49–
12.01) compared to ever-smokers with combined normal
variants, while an OR of 2.60 (95% CI: 1.00–6.67)
appeared using the same comparators amongst never-
smokers (p value of heterogeneity among the two esti-
mates = 0.49).
Discussion
This case-control study of 107 surgical cases of gastric ade-
nocarcinoma and 254 controls born in Italy evaluated the
effect on gastric cancer risk of several metabolic gene pol-
ymorphisms simultaneously. Results showed a signifi-
cantly increased risk for GSTT1 null and for SULT1A1
homozygotes, and an additional risk for NAT2 slow
acetylator individuals, although not statistically signifi-
cant. Risks associated with those genes became substan-
tive when two unfavourable genotypes were combined,
with evidence of biological interaction between them.
From the gene-environment interaction analysis, we
showed effect modification of the association between
SULT1A1 and gastric cancer by tobacco smoking, and
Table 3: Odds Ratios (95% CI) of gastric cancer for SNPs in metabolic genes according to smoking status and alcohol habits
Never-smokers (57 cases, 146 controls) Ever-smokers (50 cases, 108 controls) p for heterogeneity
cases/controls OR (95% CI) * † cases/controls OR (95% CI)
GSTM1 null 33/70 1.55 (0.83–2.90) 26/64 0.70 (0.35–1.39) 0.10
GSTT1 null 21/34 2.09 (1.06–4.11) 18/23 2.17 (1.02–4.59) 0.92
CYP1A1*2A 14/33 1.09 (0.53–2.27) 8/23 0.66 (0.27–1.61) 0.40
CYP2E1*5 4/11 0.86 (0.26–2.88) 1/9 0.20 (0.02–2.70) 0.24
CYP2E1*5A or *6 10/17 1.59 (0.67–3.79) 5/10 0.99 (0.31–3.13) 0.58
NAT2 Slow ‡ 34/77 1.39 (0.74–2.60) 30/54 1.50 (0.75–2.98) 0.87
SULT1A1 His carriers 22/62 0.86 (0.45–1.64) 27/36 2.58 (1.27–5.25) 0.03
EPHX1 exon 3 His 
carriers
28/62 1.31 (0.70–2.46) 28/56 1.12 (0.57–2.22) 0.69
EPHX4 exon 4 Arg 
carriers
21/63 0.84 (0.44–1.60) 16/38 0.89 (0.43–1.85) 0.85
Never-drinkers (32 cases, 121 controls) Ever-drinkers (73 cases, 133 controls) p for heterogeneity
cases/controls OR (95% CI) cases/controls OR (95% CI)
GSTM1 null 16/64 0.95 (0.43–2.10) 43/70 1.23 (0.69–2.20) 0.55
GSTT1 null 13/24 3.15 (1.32–7.47) 26/33 1.72 (0.92–3.22) 0.27
CYP2E1*5 0/10 - 5/10 0.86 (0.28–2.68) -
CYP2E1*5A or *6 1/19 0.18 (0.22–1.46) 14/8 3.70 (1.45–9.37) 0.001
SULT1A1 His carriers 16/51 1.42 (0.63–3.17) 33/47 1.56 (0.86–2.82) 0.98
* OR adjusted for age and gender
† Reference groups are the homozygous wild genotypes for each gene
‡ Reference group is fast acetylators (homo-heterozygous for the wild-type allele)
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CYP2E1 (*5A or *6 alleles) by alcohol drinking. In addi-
tion, our results confirm previous findings of gastric can-
cer risk to be increased by alcohol intake and family
history for cancer [27,28].
Several limitations should be taken into account in the
interpretation of our results. Firstly, based on the preva-
lence of the analyzed genotypic variants in our population
(Table 2), our study was powered to detect an OR of 2.0
for common polymorphisms (with a significance level of
5%), however not for CYP2E1*5 allele carriers,
CYP2E1*5A or *6 allele carriers and the homozygotes var-
iants of SULT1A1, EPHX3 and EPHX4. The study's sample
size limits the ability to explore the combined effects of
the genotypes, or gene-environment interactions, which
highlights the need to increase the sample size in order to
confirm our results. However, when appropriately con-
ducted, large and small studies should give, theoretically,
the same results, with just a more precise effect measure
estimate from the larger ones [29]. Secondly, as in all case-
control studies information bias may exist, leading to
biased ORs related to the gene-environment interaction
results. Thirdly, data on Helicobacter pylori infection were
not available in our population.
This is the first study conducted on an homogenous eth-
nic group who evaluated the effect on gastric cancer risk of
several metabolic genes SNPs contemporarily, and the
effect of their combination with tobacco and alcohol. One
of the main source of confounding in the genetic associa-
tion studies arises from population stratification, since the
ethnicity itself may be related to a specific disease and to
the allele frequencies as well [30,31]. Our study showed a
significant association between GSTT1 null genotype and
gastric cancer, which is in keeping with the results of a
recent meta-analysis considering only high-quality papers
[8]. Individuals who have the homozyogous deletion in
GSTT1 have no enzyme activity, and thus are more suscep-
tible to carcinogens such as benzo [D]pyrene-7,8-diol
epoxide and smaller reactive hydrocarbons, such as ethyl-
ene oxide and diepoxybutane [8]. We also reported that
individuals carriers of the SULT1A1 variant allele, who
have limited detoxification capability of xeniobiotics
through sulfonate conjugation, have an additional risk of
gastric cancer if smokers.
To our knowledge, we reported for the first time a strong
effect modification by alcohol of the association between
CYP2E1*5A or *6 alleles and gastric cancer, with an
increased risk among ever-drinkers. Two previous studies
[32,33] reported no association between CYP2E1*5A or
*6 allele and gastric cancer, however no one of them strat-
ified data according to alcohol habits. Additionally, one
study evaluating the identical association among black
South-African males showed an increased risk of oesopha-
geal cancer among drinkers carrying the CYP2E1*5A or *6
alleles [34]. CYP2E1 is a naturally ethanol-inducible
enzyme that is mainly involved in the metabolic activa-
tion of N-nitrosamines present in tobacco smoke and
some dietary compounds, for which a causative role in
gastric carcinogenesis has been hypothesised [2], and in
the metabolism of fatty acids and several halogenated and
aromatic compounds [35]. Additionally, CYP2E1 plays a
minor role in alcohol metabolism, through the oxidation
of ethanol to acetaldehyde and 1-hydroxyacetyl radicals
[35]. The *5A or *6 alleles of CYP2E1 is characterized by
some studies in an increased gene expression [36], so that
individuals carrying the unfavourable variant might be at
higher risk of gastric cancer because of: i) hyper activation
of N-nitrosamines in more reactive species, especially
Table 4: Age and gender adjusted Odds Ratios (95% CI) of gastric cancer for selected gene-gene interaction analyses
GSTT1 SULT1A1
Present Null Arg/Arg His car.
NAT2 Fast 1* 1. 38 (0.63–3.01) 1* 1.45 (0. 71–2.95)
cases/controls 30/93 13/29 23/74 20/48
Slow 1.07 (0.61–1.88) 3.00 (1.52–5.93) 1.40 (0. 75–2.60) 2.00 (1.03–3.89)
cases/controls 36/103 26/28 35/81 29/50
p for interaction† = 0.17 p for interaction = 0.97
AP‡ = 52% AP = 8%
SULT1A1 Arg/Arg 1* 1.53 (0.86–2.71) - -
cases/controls 35/122 22/34
His carriers 2.30 (1.18–4.45) 2.87 (1.36–6.05) - -
cases/controls 31/75 17/23
p for interaction = 0.70
AP = 1%
* Reference category; † By likelihood ratio test; ‡ Attributable Proportion due to biological interaction (see methods)
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among drinkers since enzyme activity is induced by alco-
hol; ii) hyper production of reactive oxygen species and
subsequent cell toxicity generated by ethanol metabolism
among drinkers. We expected to gain similar results for
CYP2E1 RsaI polymorphism, identically associated with
increased enzyme activity, however the few subjects in the
stratified analysis probably did not show it. Since these
results, however, are based on very few subjects (only one
case drinker bearing *5A or *6 alleles) they need to be
confirmed by larger studies.
Among the main results of our study, we found that
GSTT1 null genotype individuals contemporarily NAT2
slow acetylators have a strongly increased risk of gastric
cancer, with a more than just the additive effect of the risks
associated with each of the two inherited SNPs. N-acetyla-
tion is considered a major detoxification step for carcino-
genic aromatic arylamines, while GSTT1 is involved in the
detoxification of polycyclic aromatic hydrocarbons, so
individuals with one or both depleted phase II enzyme
activities might be particularly susceptible to gastric dam-
age from carcinogens, which is supported by the finding
of an additional risk for ever-smokers. We used the attrib-
utable proportion due to interaction as a measure to
quantify the biological interaction between those com-
bined SNPs and showed a strong interaction between
them. Assuming that the relationships studied are causal
and based on the definition of biological interaction
among two component causes [25,37], our results suggest
that 52% of gastric cancer cases among GSTT1 null indi-
viduals with combined NAT2 slow acetylator phenotype
are caused through a mechanism in which both risk fac-
tors are biological dependent in the same disease process.
In other words, since biological interaction among two
causes occurs when the effect of one is dependent from
the presence of the other, in the absence of either of the
two components (GSTT1 null or NAT2 slow), than a sub-
stantial number of gastric cancer cases would not occur.
Given that in our population 25% of cases had a combi-
nation of those unfavourable genotypes, this means that a
non negligible proportion of gastric cancer cases would
have never developed if those enzymatic activities were
adequate.
Conclusion
This study suggests that in this Italian population, GSTT1,
SULT1A1 and NAT2 polymorphisms may modulate an
individual's susceptibility to gastric cancer, particularly
when more than one unfavourable genotype is present
and in combination with cigarette smoke. Additionally,
we showed that individuals carrying the *5A or *6 alleles
of CYP2E1 are at increased risk for gastric cancer in drink-
ers. Clearly, since our study is based on a limited number
of cases, it is critical that larger prospective studies possi-
bly based on a single ethnic group confirms our results.
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